1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ongoing, first-in-human, phase I dose escalation study of the investigational CD47-blocker TTI-622 in patients with advanced relapsed or refractory lymphoma
    Meeting Abstract

    Patel, K.; Maris, M. B.; Cheson, B. D.; Zonder, J. A.; Lesokhin, A. M.; Von Keudell, G.; Seymour, E. K.; Lin, G. H. Y.; Catalano, T.; Shou, Y.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety and preliminary efficacy of fimepinostat plus venetoclax in patients with aggressive B-cell lymphoma
    Meeting Abstract

    Phillips, T. J.; De Vos, S.; Westin, J.; Barta, S. K.; Cohen, J. B.; Patel, K.; Smith, S. M.; Pagel, J. M.; Kansra, V.; Grayson, D.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A randomized multicenter phase II trial to evaluate the safety and efficacy of vaccination with folate receptor alpha (FRa) peptides admixed with GM-CSF as an adjuvant versus GM-CSF alone in patients with platinum-sensitive ovarian cancer (EOC)
    Meeting Abstract

    O'Cearbhaill, R. E.; Konner, J. A.; Block, M. S.; Potts, J.; Garrett, G.; Kenney, R.; Wenham, R. M.; TPIV200 Ovarian Cancer Study Group
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Effects of radiation therapy on clonal hematopoiesis
    Meeting Abstract

    Modlin, L. A.; Wijetunga, N. A.; Patel, M.; Gao, T.; Ptashkin, R.; Sullivan, M. R.; Kelly, D. W.; Caltabellotta, N.; Solit, D. B.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
    Meeting Abstract

    Mato, A. R.; Sharman, J. P.; Biondo, J.; Wu, M.; Mun, Y.; Kim, S. Y.; Humphrey, K.; Boyer, M.; Zhu, Q.; Seymour, J. F.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • PD-L1 positive esophagogastric (EG) cancer is associated with distinct bacteria
    Meeting Abstract

    Maron, S. B.; Vanderbilt, C.; Sabwa, S.; Bowman, A.; Chatila, W. K.; Tang, L. H.; Strong, V. E.; Molena, D.; Jones, D. R.; Coit, D. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Update of the phase 1/2 EVOLVE study (NCT03430011)
    Meeting Abstract

    Mailankody, S.; Jakubowiak, A. J.; Htut, M.; Costa, L. J.; Lee, K.; Ganguly, S.; Kaufman, J. L.; Siegel, D. S. D.; Bensinger, W.; Cota, M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Luo, J.; Bandlamudi, C.; Ricciuti, B.; Vokes, N.; Schoenfeld, A. J.; Egger, J. V.; Sauter, J. L.; Plodkowski, A. J.; Preeshagul, I. R.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Meeting Abstract

    Lee, H. C.; Cohen, A. D.; Chari, A.; Hultcrantz, M.; Nooka, A. K.; Callander, N. S.; Suvannasankha, A.; Badros, A.; Libby, E. N.; Trudel, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save